Ironwood Stock Price, News & Analysis

Ironwood Pharmaceuticals reported Q3 2024 results with total revenue of $91.6M, down from $113.7M in Q3 2023. LINZESS prescription demand grew 13% year-over-year, though U.S. net sales decreased 19% to $225.5M. The company maintains its 2024 financial guidance with expected U.S. LINZESS net sales of $900-950M and total revenue of $350-375M. GAAP net income was $3.6M ($0.02 per share) compared to $15.3M ($0.10 per share) in Q3 2023. The company remains on track to complete apraglutide NDA submission in Q1 2025.

Ironwood Pharmaceuticals presented new findings from the STARS Phase III trial of apraglutide at ACG 2024, showing consistent treatment effects across patient subgroups with Short Bowel Syndrome with Intestinal Failure (SBS-IF). The trial met its primary endpoint with a -25.5% vs -12.5% (p=0.001) relative change in weekly parenteral support volume at week 24 vs. placebo.

The analyses demonstrated consistent efficacy across demographics including gender, age, body weight, region, and SBS characteristics. Safety data showed high treatment compliance (>98%) with low incidence of adverse events. Ironwood expects to complete U.S. regulatory submission in Q1 2025.

Ironwood Pharmaceuticals (Nasdaq: IRWD) has scheduled its third quarter 2024 investor update conference call and webcast for Thursday, November 7, 2024, at 8:30 a.m. Eastern Time. Investors can join via phone using conference ID 2530602 or through the company's website. A replay will be available until November 21, 2024, and the webcast recording will be accessible on the company's website for one year after the call.

Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its participation in the 2024 Wells Fargo Healthcare Conference. The company will engage in a fireside chat on Thursday, September 5, 2024, at 2:15 p.m. ET at the Encore Boston Harbor.

Investors and interested parties can access a live webcast of the fireside chat through the Investors section of Ironwood's official website at www.ironwoodpharma.com. For those unable to attend or watch live, a replay of the webcast will be available on the company's website for one year following the conference.

This participation provides an opportunity for Ironwood Pharmaceuticals to engage with investors and share insights about their business and future prospects in the healthcare sector.

Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its Q2 2024 financial results. Key highlights include an 11% year-over-year increase in LINZESS® prescriptions. The company plans to complete the submission for apraglutide's NDA in Q1 2025 and expects CNP-104 topline results in Q3 2024. However, the company revised its FY 2024 guidance due to LINZESS pricing pressures from higher Medicaid utilization. Total revenue dropped to $94.4M from $107.4M in Q2 2023, and GAAP net loss was $860K, significantly improved from a loss of $1.09B year-over-year. Operating expenses were $69.4M, down from $1.19B in Q2 2023. Ironwood ended Q2 2024 with $105.5M in cash and cash equivalents. The company anticipates FY 2024 revenue between $350M and $375M, down from the initial $405M-$425M guidance.

Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its upcoming second quarter 2024 investor update conference call and webcast, scheduled for Thursday, August 8, 2024, at 8:30 a.m. Eastern Time. Interested participants can join via phone or webcast. The call replay will be available until August 22, 2024, and the webcast archive will be accessible on Ironwood's website for one year after the call.

Key details:

• Conference call-in numbers: (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international)
• Conference ID and passcode: 2530602
• Webcast access: Investors section of www.ironwoodpharma.com
• Replay numbers: (800) 770-2030 (U.S. and Canada) or (609) 800-9909 (international)

Ironwood Pharmaceuticals (Nasdaq: IRWD) announces that CFO Sravan Emany will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 a.m. ET. The event will take place at the Marriott Marquis in New York City. A live webcast of the session will be available on the Investors section of Ironwood's website, and a replay will be accessible for one year post-event.

Ironwood Pharmaceuticals presented pivotal Phase III trial data at Digestive Disease Week® 2024, highlighting the efficacy and safety of the once-weekly subcutaneous apraglutide in adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF). The trial, called STARS, showed significant reductions in weekly parenteral support (PS) volume, with apraglutide patients achieving more days off PS and higher clinical responder rates compared to placebo. Notably, some patients achieved enteral autonomy. The study demonstrated apraglutide's well-tolerated safety profile, consistent with previous trials. Ironwood plans to submit a new drug application to the FDA based on these results, potentially offering a new treatment option for SBS-IF patients.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) reported positive Phase III results for apraglutide in adult patients with SBS-IF and explored SR GI aGVHD. LINZESS EUTRx demand grew by 10% YoY. FY 2024 guidance revised due to LINZESS gross-to-net change. Financial highlights include total revenue of $74.9 million, GAAP net loss of $4.2 million, and adjusted EBITDA of $12.8 million.